Dual Implant Versus Single Implant Distal End of Femur

April 6, 2026 updated by: Justin Haller, University of Utah

Pilot for Dual Implant Versus Single Implant Distal End of Femur (pDISIDE Femur)

The investigators overall study objective is to determine the difference in outcomes for patients over 60 years of age with a displaced distal femur fracture treated with dual distal femur implants (dual plate or IMN/plate) vs. a single distal femur implant (plate or IMN).

Study Overview

Status

Enrolling by invitation

Detailed Description

The incidence of distal femur fractures in elderly patients continues to increase, most recently having an incidence of 8.7/100,000/year. This trend likely accompanies the aging population and the increased rates of knee arthroplasty. While these fractures are far less common than geriatric hip fractures, distal femur fractures present similar treatment challenges. Elderly distal femur fractures tend to occur in compromised hosts with poor bone mineral density. Similar to geriatric hip fractures, care emphasizes early mobilization to avoid the complications associated recumbency, including pneumonia, pressure sores, and venous thromboembolism. These patients are often unable to mobilize with restricted weight bearing, which places significant stress on the fixation construct. As a result, elderly patients with distal femur fractures can have high rates of morbidity and mortality.

Despite several prior studies reporting one year mortality greater than 20%, elderly distal femur fractures do not receive the same attention as geriatric hip fractures. These patient injuries are likely similar in terms of their age and comorbidities while having the same issues with post-operative mobility. Therefore, it makes sense that geriatric distal femur fracture patients and geriatric hip fracture patients have similar mortality rates. Investigators recently reported significantly greater in-hospital mortality in geriatric distal femur fractures as compared to geriatric hip fractures. A recent study of the US Medicare database is the largest study on geriatric distal femur fractures in the literature, and the overall mortality of 18.5% is similar to several prior studies ranging from 13-38%.

Distal femur fractures have traditionally been treated with operative fixation using either a lateral plate or an intramedullary nail. Advances in plate and nail technology allow for distal femur fractures to be stabilized with minimal soft tissue dissection. While recent studies suggest that early weight bearing can be tolerated with low failure rates, many surgeons continue to institute weight-bearing restrictions for osteopenic patients treated with operative fixation. Nonunion rates for operatively treated distal femur fractures have been reported to be as high as 20% in large series, leading to additional surgery to achieve union. These limitations with operative fixation have led surgeons to investigate the utility of supplementing the fixation with additional plates and/or nails.

Since many surgeons may not allow early weight bearing in osteopenic patients with operatively treated distal femur fractures, dual plating of the distal femur and locked plate/IMN combinations have become increasingly popular. Biomechanical studies have demonstrated increased torsional stiffness and axial stiffness in dual plate and plate/nail constructs as compared to single implant. A recent meta-analysis by other investigators has further demonstrated dual implants for distal femur fractures to have a low complication rate (5% nonunion) as compared to prior evidence of single implant fixation (0-25% nonunion).

In the recent study, authors reported a trend toward less one year mortality in patients treated with distal femoral replacement (DFR) (13.8%) as compared to operative fixation (22.6%) despite finding similar mortality rates at 90 days post-operatively. Since the complication rate was significantly greater in the DFR cohort, this one year mortality benefit is presumably related to early patient weight bearing after DFR that may not be permitted as frequently with operative fixation. Additionally, patients with a DFR may achieve more early mobility than operatively treated patients who are permitted immediate weight bearing due to enhanced stability in the DFR construct. Using dual implants to treat distal femur fractures may allow patients to achieve early mobility and similar mortality as a DFR patients, but have fewer post-surgical complications and less cost than a DFR.

The investigators overall study aim is to determine the difference in outcomes for patients over 60 years of age with a displaced distal femur fracture treated with dual distal femur implants (dual plate or IMN/plate) vs. a single distal femur implant (plate or IMN).

Study Type

Interventional

Enrollment (Estimated)

80

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Minnesota
      • Rochester, Minnesota, United States, 55905
        • Mayo Clinic
    • New York
      • New York, New York, United States, 10012
        • New York University
    • Oregon
      • Portland, Oregon, United States, 97239
        • Oregon Health & Science Center
    • Pennsylvania
      • Harrisburg, Pennsylvania, United States, 17101
        • University of Pittsburg Medical Center - Harrisburg
    • Utah
      • Salt Lake City, Utah, United States, 84112
        • University of Utah Orthopaedic Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

60 years to 100 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patient age 60 years or greater,
  • Femur fracture distal to the femoral diaphysis,
  • Operative treatment within 72 hours of presenting to the treating hospital,
  • Patient was previously ambulatory,
  • Fracture amendable to either single or dual implant fixation,
  • Informed consent can be obtained from the patient, family member, or power of attorney,
  • Displaced fracture (>2.5mm displacement, native or periprosthetic)

Exclusion Criteria:

  • Associated major lower extremity fracture,
  • Ongoing infection,
  • History of metabolic bone disease (Paget's, etc),
  • Pathologic fracture,
  • Gustilo-Anderson Type 3B/3C open fractures,
  • Severe cognitive impairment (Six Item Screener with 3 or more errors),
  • Stage 5 Parkinson's disease,
  • Significant femoral bone loss requiring planned staged bone grafting,
  • Vascular injury,
  • Bilateral femur fractures,
  • Unable to follow-up at treating institution for 12 months

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Single distal femur implant
Single implant constructs will be either a retrograde intramedullary nail with interlocking screws or a single plate and screw construct.
Single implant fixation
Other: Dual distal femur implants
Dual implant constructs will either be an intramedullary nail with an additional plate and screw construct or dual (two plates in any orientation) plate and screw construct.
Dual implant fixation

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Enrollment rate
Time Frame: 12-months, post-surgery
Feasibility, defined by enrollment rate (80 patients across five sites)
12-months, post-surgery
Protocol adherence
Time Frame: 12-months, post-surgery
Feasibility, defined by protocol adherence (≥90%)
12-months, post-surgery
Follow-up retention
Time Frame: 12-months, post-surgery
Feasibility, defined by follow-up retention (≥85% at 12 months)
12-months, post-surgery
Data completeness
Time Frame: 12-months, post-surgery
Feasibility, defined by data completeness (≥90%) for key secondary outcomes
12-months, post-surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Activity Measure for Post-Acute Care (AM-PAC)
Time Frame: Immediately at the day of discharge after the surgery
Activity Measure for Post-Acute Care (AM-PAC) Basic Mobility Short Form. Use 6 questions to assess functional outcomes of patients in post-acute care settings.
Immediately at the day of discharge after the surgery
Activity Measure for Post-Acute Care (AM-PAC)
Time Frame: 2-weeks, post-surgery
Activity Measure for Post-Acute Care (AM-PAC) Basic Mobility Short Form. Use 6 questions to assess functional outcomes of patients in post-acute care settings.
2-weeks, post-surgery
Activity Measure for Post-Acute Care (AM-PAC)
Time Frame: 6-weeks, post-surgery
Activity Measure for Post-Acute Care (AM-PAC) Basic Mobility Short Form. Use 6 questions to assess functional outcomes of patients in post-acute care settings.
6-weeks, post-surgery
Activity Measure for Post-Acute Care (AM-PAC)
Time Frame: 3-months, post surgery
Activity Measure for Post-Acute Care (AM-PAC) Basic Mobility Short Form. Use 6 questions to assess functional outcomes of patients in post-acute care settings.
3-months, post surgery
Activity Measure for Post-Acute Care (AM-PAC)
Time Frame: 6-months, post-surgery
Activity Measure for Post-Acute Care (AM-PAC) Basic Mobility Short Form. Use 6 questions to assess functional outcomes of patients in post-acute care settings.
6-months, post-surgery
Activity Measure for Post-Acute Care (AM-PAC)
Time Frame: 12-months, post-surgery
Activity Measure for Post-Acute Care (AM-PAC) Basic Mobility Short Form. Use 6 questions to assess functional outcomes of patients in post-acute care settings.
12-months, post-surgery
Timed Up and Go (TUG) Test
Time Frame: 6-weeks, post-surgery
The Timed Up and Go (TUG) test measures, in seconds, the time an individual takes to stand up from a chair, walk 3 meters, turn, walk back, and sit down. Generally, under 10 seconds is normal, while scores 12-14 seconds indicate a high fall risk and reduced mobility.
6-weeks, post-surgery
Timed Up and Go (TUG) Test
Time Frame: 3-months, post-surgery
The Timed Up and Go (TUG) test measures, in seconds, the time an individual takes to stand up from a chair, walk 3 meters, turn, walk back, and sit down. Generally, under 10 seconds is normal, while scores 12-14 seconds indicate a high fall risk and reduced mobility.
3-months, post-surgery
Timed Up and Go (TUG) Test
Time Frame: 6-months, post-surgery
The Timed Up and Go (TUG) test measures, in seconds, the time an individual takes to stand up from a chair, walk 3 meters, turn, walk back, and sit down. Generally, under 10 seconds is normal, while scores 12-14 seconds indicate a high fall risk and reduced mobility.
6-months, post-surgery
Timed Up and Go (TUG) Test
Time Frame: 12-months, post-surgery
The Timed Up and Go (TUG) test measures, in seconds, the time an individual takes to stand up from a chair, walk 3 meters, turn, walk back, and sit down. Generally, under 10 seconds is normal, while scores 12-14 seconds indicate a high fall risk and reduced mobility.
12-months, post-surgery
Patient Reported Outcomes Measurement Information System, Physical Function, Computerized Adaptive Testing (PROMIS Physical Function CAT)
Time Frame: 2-weeks, post-surgery

The PROMIS Physical Function T-score is a standardized score derived from a patient's responses. The T-score has a mean of 50 and a standard deviation of 10, based on a reference population (typically the U.S. general population or a specific clinical group).

A T-score above 50 indicates better-than-average physical function.

A T-score below 50 indicates below-average physical function.

2-weeks, post-surgery
Patient Reported Outcomes Measurement Information System, Physical Function, Computerized Adaptive Testing (PROMIS Physical Function CAT)
Time Frame: 6-weeks, post-surgery

The PROMIS Physical Function T-score is a standardized score derived from a patient's responses. The T-score has a mean of 50 and a standard deviation of 10, based on a reference population (typically the U.S. general population or a specific clinical group).

A T-score above 50 indicates better-than-average physical function.

A T-score below 50 indicates below-average physical function.

6-weeks, post-surgery
Patient Reported Outcomes Measurement Information System, Physical Function, Computerized Adaptive Testing (PROMIS Physical Function CAT)
Time Frame: 12-weeks, post-surgery

The PROMIS Physical Function T-score is a standardized score derived from a patient's responses. The T-score has a mean of 50 and a standard deviation of 10, based on a reference population (typically the U.S. general population or a specific clinical group).

A T-score above 50 indicates better-than-average physical function.

A T-score below 50 indicates below-average physical function.

12-weeks, post-surgery
Patient Reported Outcomes Measurement Information System, Physical Function, Computerized Adaptive Testing (PROMIS Physical Function CAT)
Time Frame: 24-weeks, post-surgery

The PROMIS Physical Function T-score is a standardized score derived from a patient's responses. The T-score has a mean of 50 and a standard deviation of 10, based on a reference population (typically the U.S. general population or a specific clinical group).

A T-score above 50 indicates better-than-average physical function.

A T-score below 50 indicates below-average physical function.

24-weeks, post-surgery
Patient Reported Outcomes Measurement Information System, Physical Function, Computerized Adaptive Testing (PROMIS Physical Function CAT)
Time Frame: 52-weeks, post-surgery

The PROMIS Physical Function T-score is a standardized score derived from a patient's responses. The T-score has a mean of 50 and a standard deviation of 10, based on a reference population (typically the U.S. general population or a specific clinical group).

A T-score above 50 indicates better-than-average physical function.

A T-score below 50 indicates below-average physical function.

52-weeks, post-surgery
Patient Reported Outcomes Measurement Information System-29 (PROMIS-29)
Time Frame: 2-weeks, post-surgery
Patient-reported outcome tool measuring health across seven core domains (physical function, anxiety, depression, fatigue, sleep disturbance, pain interference, and social roles) using 29 items, plus a 0-10 pain intensity rating. Most domains are expressed as T-scores, where 50 is the average for the US general population with a standard deviation (SD) of 10. Higher scores mean "more" of the domain.
2-weeks, post-surgery
Patient Reported Outcomes Measurement Information System-29 (PROMIS-29)
Time Frame: 6-weeks, post-surgery
Patient-reported outcome tool measuring health across seven core domains (physical function, anxiety, depression, fatigue, sleep disturbance, pain interference, and social roles) using 29 items, plus a 0-10 pain intensity rating. Most domains are expressed as T-scores, where 50 is the average for the US general population with a standard deviation (SD) of 10. Higher scores mean "more" of the domain.
6-weeks, post-surgery
Patient Reported Outcomes Measurement Information System-29 (PROMIS-29)
Time Frame: 12-weeks, post-surgery
Patient-reported outcome tool measuring health across seven core domains (physical function, anxiety, depression, fatigue, sleep disturbance, pain interference, and social roles) using 29 items, plus a 0-10 pain intensity rating. Most domains are expressed as T-scores, where 50 is the average for the US general population with a standard deviation (SD) of 10. Higher scores mean "more" of the domain.
12-weeks, post-surgery
Patient Reported Outcomes Measurement Information System-29 (PROMIS-29)
Time Frame: 24-weeks, post-surgery
Patient-reported outcome tool measuring health across seven core domains (physical function, anxiety, depression, fatigue, sleep disturbance, pain interference, and social roles) using 29 items, plus a 0-10 pain intensity rating. Most domains are expressed as T-scores, where 50 is the average for the US general population with a standard deviation (SD) of 10. Higher scores mean "more" of the domain.
24-weeks, post-surgery
Patient Reported Outcomes Measurement Information System-29 (PROMIS-29)
Time Frame: 52-weeks, post-surgery
Patient-reported outcome tool measuring health across seven core domains (physical function, anxiety, depression, fatigue, sleep disturbance, pain interference, and social roles) using 29 items, plus a 0-10 pain intensity rating. Most domains are expressed as T-scores, where 50 is the average for the US general population with a standard deviation (SD) of 10. Higher scores mean "more" of the domain.
52-weeks, post-surgery
Infections
Time Frame: 3-months, post-surgery
Incidents of infections (CDC criteria)
3-months, post-surgery
Readmissions
Time Frame: 3-months, post-surgery
Incidents of 90-day readmissions
3-months, post-surgery
Complications
Time Frame: 3-months, post-surgery
Incidents of mortality
3-months, post-surgery
Complications
Time Frame: 12-months, post-surgery
Incidents of mortality, nonunion, implant failure, unplanned reoperation
12-months, post-surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Justin Haller, M.D., University of Utah Orthopaedics

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 14, 2022

Primary Completion (Estimated)

February 1, 2027

Study Completion (Estimated)

February 1, 2027

Study Registration Dates

First Submitted

March 14, 2022

First Submitted That Met QC Criteria

March 14, 2022

First Posted (Actual)

March 23, 2022

Study Record Updates

Last Update Posted (Actual)

April 13, 2026

Last Update Submitted That Met QC Criteria

April 6, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Distal Femur Fracture

Clinical Trials on Single distal femur implant

Subscribe